ArticleBioprocess and biosystems engineering2026
Integrated dual carbon source and TCA intermediate supplementation in fed-batch fermentation of CHO cells for reduced lactate and ammonia accumulation and improved IgG1 monoclonal antibody titre.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chinese hamster ovary (CHO) cells are the workhorse of biopharmaceutical manufacturing, yet lactate and ammonia accumulation remain persistent bottlenecks that compromise cell viability, productivity, and product quality. To address this, we present an integrated feeding strategy systematically combining Ala-Gln, TCA intermediates, and glucose-galactose dual carbon feed evaluated head-to-head across four defined fed-batch conditions for CHO cultures producing an IgG1 monoclonal antibody (mAb). Conventional L-glutamine was replaced with L-alanyl-glutamine (Ala-Gln) to curb spontaneous ammonia release, while a customized "efficient feed mix" enriched with 2× TCA cycle intermediates and branched-chain amino acids combined with a glucose-galactose co-feed (2 mM glucose + 30 mM galactose) was introduced upon glucose depletion. Four fed-batch conditions were evaluated: a glutamine control (FB-01), Ala-Gln alone (FB-02), Ala-Gln with TCA intermediates (FB-03), and the complete integrated strategy (FB-04). FB-04 delivered an > 83% reduction in peak lactate (4.0 mM) and 80% reduction in ammonia (< 2.0 mM), sustained cell viability above 85% through day 11, and achieved a 93% higher mAb titre (1.72 g/L) with peak Viable count density (VCD) of 39 × 10⁶ cells/mL. Glycosylation profiles (19.0% galactosylation) remained aligned with innovator benchmarks. This study presents the first direct head-to-head benchmarking of Ala-Gln substitution, TCA intermediate supplementation, and galactose co-feeding in a single CHO fed-batch platform, demonstrating their combined metabolic and glycosylation benefits against a glutamine control.
Indexed as
Identifiers
42886232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.